Shares of Agenus Inc. (NASDAQ:AGEN) shot up 0% during trading on Friday . The company traded as high as $3.74 and last traded at $3.73. 1,591,553 shares were traded during mid-day trading, an increase of 32% from the average session volume of 1,207,107 shares. The stock had previously closed at $3.73.

A number of brokerages recently commented on AGEN. BidaskClub lowered Agenus from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Agenus from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $7.00 price objective on shares of Agenus in a report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $5.81.

The company has a current ratio of 1.55, a quick ratio of 3.36 and a debt-to-equity ratio of -2.39.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, hitting analysts’ consensus estimates of ($0.37). The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $5.91 million. Agenus’s quarterly revenue was down 24.4% on a year-over-year basis. equities analysts anticipate that Agenus Inc. will post -1.19 EPS for the current fiscal year.

In other Agenus news, CEO Garo H. Armen bought 100,000 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were purchased at an average price of $3.55 per share, for a total transaction of $355,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 7.60% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Agenus by 511.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 88,942 shares of the biotechnology company’s stock worth $392,000 after buying an additional 74,407 shares during the last quarter. Artal Group S.A. boosted its stake in shares of Agenus by 25.0% in the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock worth $11,025,000 after buying an additional 500,000 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Agenus by 12.8% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock worth $2,724,000 after buying an additional 70,000 shares during the last quarter. Swiss National Bank boosted its stake in shares of Agenus by 15.9% in the 3rd quarter. Swiss National Bank now owns 149,200 shares of the biotechnology company’s stock worth $658,000 after buying an additional 20,500 shares during the last quarter. Finally, Chicago Equity Partners LLC boosted its stake in shares of Agenus by 13.7% in the 3rd quarter. Chicago Equity Partners LLC now owns 350,135 shares of the biotechnology company’s stock worth $1,544,000 after buying an additional 42,085 shares during the last quarter. Hedge funds and other institutional investors own 39.56% of the company’s stock.

WARNING: “Agenus Inc. (AGEN) Shares Up 0%” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/agenus-inc-agen-shares-up-0/1698068.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.